journal
MENU ▼
Read by QxMD icon Read
search

Hematological Oncology

journal
https://www.readbyqxmd.com/read/27878835/first-line-therapy-for-chronic-lymphocytic-leukemia-in-patients-older-than-79%C3%A2-years-is-feasible-and-achieves-good-results-a-filo-retrospective-study
#1
Godelieve Meunier, Loic Ysebaert, Phi Linh Nguyen-Thi, Stéphane Lepretre, Anne Quinquenel, Jehan Dupuis, Richard Lemal, Thérèse Aurran, Cécile Tomowiak, Florence Cymbalista, Marie Sarah Dilhuydy, Annie Brion, Pierre Morel, Bruno Cazin, Véronique Leblond, Guillaume Cartron, Daniel Ré, Marie Christine Béné, Anne Sophie Michallet, Pierre Feugier
The mean age at diagnosis of chronic lymphocytic leukemia (CLL) is 72 years, with 22.8% of patients being older than 80 years. However, the elderly are underrepresented in clinical studies of CLL. We performed a retrospective study of CLL patients aged 80 years or older at the initiation of first-line therapy in hospitals affiliated with the French intergroup on CLL (French Innovative Leukemia Organization) between 2003 and 2013. Here, we describe the clinical and biological characteristics, treatment, and outcomes for 201 patients...
November 22, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27859456/clinical-characteristics-and-survival-outcome-of-primary-effusion-lymphoma-a-review-of-105-patients
#2
Mohamed Abd El-Fattah
Primary effusion lymphoma (PEL) is a rare and an aggressive B-cell non-Hodgkin lymphoma with a distinctive clinicobiological features. As a result of the rarity of this malignancy, the overwhelming majority of data come from a case reports or series. Our study aimed to evaluate the clinical features and the survival outcomes of 105 patients with PEL who diagnosed between 2001 and 2012 from the Surveillance Epidemiology and End Results database 18 of the US National Cancer Institute. The Kaplan-Meier curves were constructed and the multivariate Cox model was built to identify survival prognostic factors...
November 18, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27862141/outpatient-experience-with-biosimilar-filgrastim-in-patients-with-lymphoid-neoplasm-lessons-from-daily-clinical-practice
#3
LETTER
Lisa Argnani, Alessandro Broccoli, Cinzia Pellegrini, Beatrice Casadei, Pier Luigi Zinzani
No abstract text is available yet for this article.
November 10, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27813134/establishment-and-characterization-of-a-novel-hodgkin-lymphoma-cell-line-am-hlh-carrying-the-epstein-barr-virus-genome-integrated-into-the-host-chromosome
#4
Masahiko Hayashida, Masanori Daibata, Erika Tagami, Takahiro Taguchi, Fumiyo Maekawa, Kayo Takeoka, Katsuhiro Fukutsuka, Daiki Shimomura, Takamasa Hayashi, Yoshinori Iwatani, Hitoshi Ohno
We describe the establishment and characterization of a cell line, AM-HLH, obtained from a patient with Epstein-Barr virus-positive (EBV(+) ) nodular sclerosis-type Hodgkin lymphoma (HL). The cells were positive for CD2 and CD30 and negative for CD15. The immunoglobulin heavy- and κ light-chain genes were rearranged. The karyotype was of the triploid range. Southern blotting using the EBV terminal repeat probe detected 3 hybridizing bands that were identical to those of the parental HL material. The cells expressed EBV-encoded RNAs as well as latent genes (EBNA1, EBNA2, LMP1, and LMP2A) and lytic genes (BZLF1 and BALF2)...
November 4, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27804161/monoclonal-gammopathy-of-undetermined-significance-mgus-and-smoldering-myeloma-smm-a-practical-guide-to-management
#5
Nicola Maciocia, Ashutosh Wechalekar, Kwee Yong
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma are precursor conditions of symptomatic multiple myeloma (MM). Diagnostic principles are aimed at excluding MM requiring therapy, other conditions associated with paraproteins that may require different management, and risk stratifying patients for the purposes of tailored follow-up and investigation. The International Myeloma Working Group have recently published a revised definition of MM, which singles out a small group of patients with smoldering multiple myeloma who are at very high risk of progression and organ damage; such patients are now included under the definition of MM and recommended to start anti-myeloma treatment...
November 2, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27791277/neutrophil-lymphocyte-ratio-at-diagnosis-is-an-independent-prognostic-factor-in-patients-with-nodular-sclerosis-hodgkin-lymphoma-results-of-a-large-multicenter-study-involving-990-patients
#6
Raffaella Marcheselli, Alessia Bari, Tamar Tadmor, Luigi Marcheselli, Maria Christina Cox, Samantha Pozzi, Angela Ferrari, Luca Baldini, Paolo Gobbi, Ariel Aviv, Giuseppe Pugliese, Massimo Federico, Aaron Polliack, Stefano Sacchi
Several studies have demonstrated the prognostic value of neutrophil-lymphocyte ratio (NLR) in patients with solid tumors and non-Hodgkin lymphoma. In contrast, there is only sparse data on its prognostic role in patients with classical Hodgkin lymphoma (cHL). The aim of our study was to establish whether NLR could serve as an independent prognostic factor in a cohort of 990 patients with nodular sclerosis (NS)-cHL. After analysis of the log hazard ratio (HR) as a function of NLR, we chose the value 6 as cutoff...
October 28, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27781293/methotrexate-elimination-and-toxicity-mthfr-677c-t-polymorphism-in-patients-with-primary-cns-lymphoma-treated-with-high-dose-methotrexate
#7
Yun Jung Choi, Hyangmin Park, Ji Sung Lee, Ju-Yeon Lee, Shin Kim, Tae Won Kim, Jung Sun Park, Jeong Eun Kim, Dok Hyun Yoon, Cheolwon Suh
The genetic association of the methylenetetrahydrofolate reductase gene (MTHFR) 677C>T polymorphism with methotrexate (MTX)-associated toxicity has been evaluated and conflicting results have been reported. The substantial heterogeneity of the studied population was suggested to be a possible explanation because ethnicity, MTX dose, coadministered chemotherapeutic agents, and folinate rescue dosage regimen could alter the MTX toxicity profile. The patient population was homogenized by limiting the cancer type to primary central nervous system lymphoma and chemotherapy protocol to a high-dose MTX monotherapy regimen...
October 25, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27781290/low-dose-radiotherapy-in-diffuse-large-b-cell-lymphoma
#8
Carlo Furlan, Vincenzo Canzonieri, Michele Spina, Mariagrazia Michieli, Anna Ermacora, Roberta Maestro, Sara Piccinin, Riccardo Bomben, Michele Dal Bo, Marco Trovo, Valter Gattei, Umberto Tirelli, Giovanni Franchin, Pietro Bulian
Low-dose radiotherapy (LDRT) given in 2 × 2 Gy is a highly effective and safe treatment for palliation of indolent lymphomas. Otherwise, very little regarding the use of LDRT for diffuse large B-cell lymphoma (DLBCL) has been investigated. We designed a phase 2 trial of LDRT in patients with DLBCL with indication for palliative radiation. Low-dose radiotherapy was administered on symptomatic areas only. Clinical response was assessed 21 days after LDRT and defined as reduction >50% of maximum diameter of the radiated lesions...
October 25, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27766647/the-effect-of-microenvironmental-factors-on-the-development-of-myeloma-cells
#9
Ágnes Márk, Gergely Varga, Botond Timár, Csilla Kriston, Orsolya Szabó, Linda Deák, András Matolcsy, Gábor Barna
Multiple myeloma (MM) is a clonal B-cell malignancy characterized by the accumulation of monoclonal plasma cells (PCs) in the bone marrow and other tissues. Although there are several new therapies, MM remains fatal. The interaction between MM cells and the bone marrow microenvironment promotes drug resistance and cancer cells survival. In our present work, we compared the antigen expression pattern of normal and pathological PCs and investigated the possible connections between various surface receptors, adhesion molecules, and recurrent genetic aberrations...
October 21, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27761934/allogeneic-hematopoietic-stem-cell-transplantation-for-paroxysmal-nocturnal-hemoglobinuria-a-retrospective-single-center-study
#10
Hosein Kamranzadeh Fumani, Mohammad Zokaasadi, Amir Kasaeian, Kamran Alimoghaddam, Seyed Asadollah Mousavi, Babak Bahar, Mohammad Vaezi, Ardeshir Ghavamzadeh
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal disease of hematopoietic stem cell characterized by complement mediated intravascular hemolysis. There are different treatment modalities available for PNH, such as supportive care, eculizumab, and hematopoietic stem cell transplantation (HSCT); only the last one has a potential curative role. This study reported the outcome of HSCT transplanted PNH patients. Thirteen PNH patients between 2002 and 2014 participated in this study. All had full-matched sibling donors, and the conditioning regimen was Bu/Cy (busulfan plus cyclophosphamide), and the source of stem cells was peripheral blood of the donors...
October 20, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27734526/human-myeloid-inhibitory-c-lectin-a-highly-specific-and-stable-acute-myeloid-leukemia-marker
#11
Deena Samir Eissa, Eman Zaghloul Kandeel, Mohamed Ghareeb
The prognosis of acute myeloid leukemia (AML) is poor because of relapses occurring on conventional chemotherapy. The distinction between leukemic and normal stem cells relies on the expression of antigen combinations defining leukemia-associated immunophenotypes (LAIPs), which are absent or extremely infrequent in normal bone marrow. However, LAIPs are very different from patient to patient and are not necessarily stable over the course of the disease. Accordingly, we addressed the applicability of human myeloid inhibitory C-lectin (hMICL) by flow cytometry as a specific leukemic myeloid stem cell marker for the diagnosis of AML in CD34(+) and CD34(-) cases and evaluated the stability of hMICL during the course of the disease...
October 13, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27734524/bendamustine-associated-infections-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#12
Anat Gafter-Gvili, Ronit Gurion, Pia Raanani, Ofer Shpilberg, Liat Vidal
Data in the literature are lacking regarding the infection-related adverse events of bendamustine-containing regimens. Therefore, we aimed to assess this risk. We conducted a systematic review and meta-analysis of all randomized controlled trials including bendamustine-containing regimens and those administered for any lymphoproliferative disorder or plasma cell dyscrasia compared with any other regimens. A comprehensive search was conducted until December 2015. Two reviewers appraised the quality of trials and extracted data...
October 13, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27734522/detection-of-l265p-myd-88-mutation-in-a-series-of-clonal-b-cell-lymphocytosis-of-marginal-zone-origin-cbl-mz
#13
Christina Kalpadakis, Gerassimos A Pangalis, Theodoros P Vassilakopoulos, Maria Roumelioti, Sotirios Sachanas, Penelope Korkolopoulou, Efstathios Koulieris, Maria Moschogiannis, Xanthi Yiakoumis, Pantelis Tsirkinidis, Charalampos Pontikoglou, Dimitra Rondoyianni, Helen A Papadaki, Panayiotidis Panayiotidis, Maria K Angelopoulou
Clonal B-cell lymphocytosis of marginal zone origin (CBL-MZ) is a recently described entity characterized by the presence of clonal B cells in the blood and/or bone marrow (BM) with morphologic and immunophenotypic features consistent with marginal zone derivation in otherwise healthy individuals. CBL-MZ is commonly associated with paraproteinemia, usually immunoglobulin M (IgM), raising diagnostic difficulties from Waldenstrom macroglobulinemia (WM). The aim of the present study was to determine the presence of MYD-88 L265P mutation in a well-characterized series of CBL-MZ to identify cases that may in fact represent WM...
October 13, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27734521/enteroviral-infection-in-patients-treated-with-rituximab-for-non-hodgkin-lymphoma-a-case-series-and-review-of-the-literature
#14
S Grisariu, I Vaxman, M Gatt, S Elias, B Avni, A Arad, O Pasvolsky, P Raanani, O Paltiel
In recent years, anti-CD20 antibodies have been increasingly used to treat lymphoproliferative and immune disorders. Chronic viral infections are infrequently reported in patients receiving these therapies. Enteroviral infection can cause life-threatening meningoencephalitis and other systemic chronic syndromes in immune deficient patients. We describe the clinical courses and outcomes of 6 patients from 2 tertiary care institutions who developed chronic enteroviral infection with neurological manifestations, after combined chemoimmunotherapy with rituximab for B-cell lymphoma...
October 13, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27734516/follicular-dendritic-cell-sarcoma-treated-with-a-variety-of-chemotherapy
#15
Masaoki Sasaki, Hiroaki Izumi, Takaaki Yokoyama, Motohiro Kojima, Ako Hosono
Follicular dendritic cell sarcoma (FDCS) is a very rare malignant tumor derived from follicular dendritic cells. Radical resection is the standard therapy for patients with local disease, but an optimal chemotherapy regimen has not been determined for unresectable disease. We report our experience of an FDCS patient with multiorgan involvement. In the present case, disease was only located in the pancreas initially and radical resection was performed. Multiple metastasis developed after the treatment and several factors that indicated a poor prognosis were observed...
October 13, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27723108/a-phase-2-study-of-methotrexate-etoposide-dexamethasone-and-pegaspargase-chemotherapy-for-newly-diagnosed-relapsed-or-refractory-extranodal-natural-killer-t-cell-lymphoma-nasal-type-a-multicenter-trial-in-northwest-china
#16
Rong Liang, Guang-Xun Gao, Jie-Ping Chen, Ji-Shi Wang, Xiao-Min Wang, Yun Zeng, Qing-Xian Bai, Tao Zhang, Lan Yang, Bao-Xia Dong, Hong-Tao Gu, Mi-Mi Shu, Cai-Xia Hao, Jian-Hong Wang, Na Zhang, Xie-Qun Chen
The nasal type of extranodal natural killer/T-cell lymphoma is a rare aggressive lymphoma with poor prognosis. To discover a successful treatment, we investigated the efficacy and safety of chemotherapy with methotrexate, etoposide, dexamethasone, and polyethylene glycol-asparaginase (MESA). Three cycles of MESA were administered to 46 patients with new or relapsed/refractory natural killer/T-cell lymphoma. Complete response after 3 treatment cycles was 43.5%, the overall response rate was 87%, and 2-year overall survival was 83...
October 10, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27709652/circulating-epstein-barr-virus-encoded-micro-rnas-as-potential-biomarkers-for-nasal-natural-killer-t-cell-lymphoma
#17
Yuki Komabayashi, Kan Kishibe, Toshihiro Nagato, Seigo Ueda, Miki Takahara, Yasuaki Harabuchi
Nasal natural killer/T-cell lymphoma (NNKTL) is an Epstein-Barr virus (EBV)-associated malignancy and is characterized by local invasion and widespread dissemination, with a consequent poor prognosis. Micro-RNAs (miRNAs) play roles in the pathogenesis of several malignancies by regulating gene expression and have been recently identified as stable entities in serum. Here, we investigated the value of circulating EBV-miRNAs as biomarkers for NNKTL. Sera of patients with NNKTL were subjected to miRNA polymerase chain reaction (PCR)-array analysis, after which serum EBV-miRNA levels were verified using quantitative PCR...
October 6, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27704586/hypermethylation-of-prdm1-blimp-1-promoter-in-extranodal-nk-t-cell-lymphoma-nasal-type-an-evidence-of-predominant-role-in-its-downregulation
#18
Zhang Zhang, Li Liang, Dong Li, Lin Nong, Jumei Liu, Linlin Qu, Yalin Zheng, Bo Zhang, Ting Li
The loss of PRDM1 expression is common in extranodal NK/T-cell lymphoma, nasal type (EN-NK/T-NT), but the role of promoter methylation in silencing PRDM1 expression remains unclear. Hence, we performed pyrosequencing analysis to evaluate the promoter methylation of PRDM1 gene in vivo and in vitro, to analyze the association between methylation and its expression, and to assess cellular effects of PRDM1 reexpression. The promoter hypermethylation of PRDM1 gene was detected in 11 of 25 EN-NK/T-NT cases (44.0%) and NK92 and NKL cells...
October 5, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27678008/major-prognostic-value-of-complex-karyotype-in-addition-to-tp53-and-ighv-mutational-status-in-first-line-chronic-lymphocytic-leukemia
#19
Yannick Le Bris, Stéphanie Struski, Romain Guièze, Caroline Rouvellat, Naïs Prade, Xavier Troussard, Olivier Tournilhac, Marie C Béné, Eric Delabesse, Loïc Ysebaert
Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disorder of remarkable heterogeneity as demonstrated by cytogenetics and molecular analyses. Complex karyotype (CK), TP53 deletions and/or mutations (TP53 disruption), IGVH mutational status, and, more recently, recurrent somatic mutations have been identified as prognostic markers in CLL. On a cohort of 110 patients with CLL treated with first-line fludarabin, cyclophosphamide, and rituximab treatment compared with 33 untreated (watch and wait) patients with CLL, we report more frequent complex karyotypes (34 vs 15%; P = ...
September 28, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27677906/y-90-ibritumomab-tiuxetan-y-90-it-and-high-dose-melphalan-as-conditioning-regimen-before-autologous-stem-cell-transplantation-for-elderly-patients-with-lymphoma-in-relapse-or-resistant-to-chemotherapy-a-feasibility-trial-sakk-37-05
#20
Michèle Voegeli, Stephanie Rondeau, Simona Berardi Vilei, Erika Lerch, Luciano Wannesson, Thomas Pabst, Jochen Rentschler, Mario Bargetzi, Lorenz Jost, Nicolas Ketterer, Angelika Bischof Delaloye, Michele Ghielmini
Standard conditioning regimens for autologous stem cell transplantation (ASCT) are often not tolerated by elderly patients, on one hand. Single high-dose melphalan, on the other hand, has been shown to be safe and active as a pretransplant preparative regimen in elderly patients. Y(90) -Ibritumomab tiuxetan (Y(90) -IT) is well tolerated and feasible in the transplantation setting. We therefore investigated the combination of high-dose melphalan and Y(90) -IT as a conditioning regimen for patients ≥65 years of age...
September 28, 2016: Hematological Oncology
journal
journal
28626
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"